Beckman Coulter, Inc.

Beckman Coulter, Inc., through its US Customer Operations Division, manufactures automated clinical laboratory diagnostic equipment, reagents, consumables, and cost-per-reportable-result testing services to federal healthcare agencies as a full-and-open prime contractor (100% of awards in the source). The division, headquartered in Brea, California, is a subsidiary of Danaher Corporation and operates without SBA set-aside status, competing exclusively in unrestricted federal procurement. Beckman Coulter's federal footprint centers on urinalysis, hematology, chemistry, immunochemistry, and microbiology analyzers delivered through the GSA Critical Analyzers, Laboratory (FSS-66-III) Federal Supply Schedule, which carries 5,532 task orders valued at $1.94 billion in combined potential value across the federal government.

The vendor's customer concentration is acute and Veterans Health Administration–dominant. The top five funding agencies by award count account for 27 percent of recent awards and represent a combined potential value of $635.1 million. Veterans Integrated Service Network 16 leads both rankings by count (1,003 awards, $396.8 million combined potential value) and by dollar magnitude, followed closely by VISN 17 (425 awards, $353.7 million). VISN 4, VISN 21, and VISN 10 round out the top five by dollars. The Department of the Navy Bureau of Medicine and Surgery and Department of the Army Medical Command represent the primary defense healthcare customers, with $94.9 million and $109.6 million in combined potential value respectively. The Indian Health Service accounts for $30.6 million across 494 awards. Outside the Veterans Health Administration, Beckman Coulter has worked with 144 distinct customer agencies; concentration within the VA system is correspondingly high—the top five VISNs account for approximately $1.11 billion in combined potential value across 2,819 awards, representing roughly 28 percent of the vendor's total federal portfolio by dollars.

Beckman Coulter holds a dominant, single-source position on the Critical Analyzers, Laboratory (FSS-66-III) Federal Supply Schedule. The 5,552 task orders on this vehicle alone carry $1.95 billion in combined potential value, dwarfing all other parent vehicles. A secondary Federal Supply Schedule (V797P6553A) carries 2,894 task orders valued at $172.3 million, and other schedules and BPAs are substantially smaller. The vendor operates numerous single-award blanket purchase agreements with individual VISNs—documented IDVs include a $3.1 million VISN 4 microbiology BPA through November 2030, a $2.52 million VISN 12 urinalysis BPA through February 2027, a $1.11 million VISN 17 hematology BPA through January 2027, and a $740 million Defense Health Agency single-award IDIQ for CBC testing through June 2031. The vendor also holds a $5.91 million Bureau of Medicine and Surgery indefinite delivery contract for Beckman Coulter AU5800 series analyzer consumables serving five Department of Defense drug testing laboratories.

Recent activity shows moderate volume across a large award base. Beckman Coulter has received 120 awards in 2026 (through December 1), 279 in 2025, and 307 in 2024, representing a relatively stable procurement level across the past three years. Over the next twenty-four months, 152 awards totaling $134.2 million are scheduled for ultimate completion, creating a moderate recompete cliff primarily concentrated within the VA system and requiring vendor recompetition or renewal to maintain continuity across the federal healthcare network.

The vendor's work is structured almost entirely around cost-per-reportable-result (CPRR) and cost-per-test pricing models. Representative recent awards include a $4.69 million VISN 2 chemistry CPRR delivery order through September 2026, a $2.99 million VISN 19 chemistry and immunochemistry CPRR BPA call through July 2027, a $2.92 million VISN 16 chemistry task order through September 2026, a $5.91 million Bureau of Medicine and Surgery AU5800 analyzer consumables contract serving five DoD drug testing labs through June 2031, a $3.57 million Bureau of Medicine and Surgery maintenance and repair service contract for AU5800 series analyzers at Portsmouth, Virginia through March 2031, and a $2.99 million Defense Health Agency cost-per-reportable-result automated core laboratory contract through September 2027. Beckman Coulter also supplies equipment leasing and maintenance services on a firm fixed-price basis—a $939 thousand Defense Health Agency lease of a PK7400 analyzer at Lackland Air Force Base through May 2029, a $905 thousand Defense Health Agency wet chemistry and immunoassay platform lease at Tampa through March 2032, and a $764 thousand Defense Health Agency three-analyzer urinalysis lease at Fort Bliss through September 2030 exemplify this modality.

Beckman Coulter operates as a pure prime contractor; the source identifies only one sub-award—a December 2024 sub-award under Consolidated Nuclear Security, LLC's Y-12 National Security Complex management contract. All 13,857 documented awards in the source span 1988 to present; the vendor's federal engagement predates the 2026 timeframe by decades. The vendor's activity is concentrated in the Clinical Laboratory Instrument Manufacturing and In-Vitro Diagnostic Substance Manufacturing NAICS categories, with secondary strength in laboratory equipment repair and medical laboratory services. The vendor does not pursue or hold positions on any observed DOD, civilian agency, or multi-agency GWAC vehicles outside the GSA Critical Analyzers, Laboratory schedule; its vehicle footprint is narrowly specialized to clinical laboratory diagnostic procurement.

Beckman Coulter competes without set-aside status across all major customer relationships, indicating both the breadth of its federal market presence and the absence of small-business, HUBZone, SDVOSB, WOSB, or 8(a) positioning. The vendor's $1.41 billion in obligated dollars against a $3.91 billion combined potential value indicates 36 percent realization across the award base—typical for multi-year IDV and schedule vehicles where ceiling values exceed near-term spending authority. The vendor's dominance on the Critical Analyzers schedule and concentration among Veterans Integrated Service Networks position it as the incumbent federal healthcare laboratory diagnostics supplier, with limited direct competitors for the majority of its customer base and contract vehicles.